Biosimilar switching isn’t a procurement problem—it’s a patent strategy problem.
If you’re planning a biosimilar switch, you’re probably thinking about pricing, contracting, and supply. Those matter. But the real question is simpler—and harder:
When ca…

Old Drugs. New Prices. The Pharma Playbook That’s Quietly Reshaping Healthcare.
There’s a familiar story in healthcare right now: a medicine that’s been around for years—sometimes decades—suddenly gets a new price tag. Not because the science changed o…

Pharma hiring is broken in a very specific way.
Recruiters often chase the loudest signals—titles, conference appearances, “years of experience,” maybe a keyword match on a resume. But in drug development, the most valuable signal is usually quieter: w…

Pharma has a new playbook—and it’s not always about new science.
In a world where patients are increasingly asked to “wait for innovation,” drugmakers are finding another path to premium pricing: repurposed medicines. The headline may sound familiar—“o…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” is becoming the main engine. Here’s what patent filings are quietly signaling about APIs and full-cycle drug production.
If you’ve ever heard the phrase “the third wheel rule” in the context of Russia’s industrial policy, you mig…

Europe’s divisional patent strategy is one of those quiet mechanisms that rarely makes headlines—until you realize it can delay access to cheaper medicines for years.
Here’s the hook: Big Pharma doesn’t always need to “win” a patent fight to protect pr…

Pharma patent litigation used to be a $50M bet.
Now, in too many cases, it’s a $5M strategy.
That’s not a typo—and it’s not just about “spending less.” It’s about changing the way companies think, plan, and execute when the clock starts ticking on Hatc…

PBMs don’t just “manage formularies.” They shape the economics of every branded drug in the U.S.—often long before a patient ever sees a prescription.
And if you’re a pharma executive, the uncomfortable truth is this: the formulary and rebate conversat…

Mark Cuban’s cost-plus pricing isn’t just a new way to buy drugs—it’s a direct challenge to the industry’s oldest playbook.
For decades, the pharmaceutical model has relied on a familiar sequence: patents grant exclusivity, prices rise to recoup R&…